Valuation: Samik Pharmaceutical Company LTD.

Market Cap 55.74B 37.63M 32.89M 30.42M 27.91M 52.83M 3.63B 53.75M 363M 143M 1.77B 141M 138M 6.11B P/E 2024 *
-
P/E 2025 -140x
Enterprise Value 26.69B 18.02M 15.75M 14.57M 13.37M 25.3M 1.74B 25.74M 174M 68.24M 848M 67.67M 66.18M 2.93B EV / Sales 2024 *
-
EV / Sales 2025 1.65x
Free-Float
38.95%
Yield 2024 *
-
Yield 2025 -
1 day+29.84%
1 week+34.38%
Current month-13.91%
1 month-16.11%
3 months-46.29%
6 months-71.20%
Current year-60.13%
1 week 3,705
Extreme 3705
5,570
1 month 3,705
Extreme 3705
10,650
Current year 3,705
Extreme 3705
21,800
1 year 3,705
Extreme 3705
25,050
3 years 3,705
Extreme 3705
25,050
5 years 3,705
Extreme 3705
25,050
10 years 3,705
Extreme 3705
25,050
Manager TitleAgeSince
Chief Executive Officer 64 2016-11-30
Chief Executive Officer 59 2011-05-31
Corporate Officer/Principal 56 2018-07-31
Director TitleAgeSince
Chairman 59 2011-05-31
Chairman 64 2016-11-30
Director/Board Member 66 2024-02-29
Change 5-day change 1-year change 3-year change Capi.($)
+29.84%+34.38% - - 37.63M
+1.08%-3.93%+48.03%+160.13% 1,043B
+1.19%-3.52%+51.70%+56.36% 602B
+4.21%+1.79%+33.48%+87.04% 449B
+1.30%-0.30%+30.58%+25.13% 327B
+1.53%+0.31%+33.55%+46.80% 279B
-0.17%-2.09%+21.86%+23.20% 264B
+3.70%+2.19%+24.27%+63.38% 201B
+3.49%+1.08%+24.08%+76.58% 169B
+1.29%+3.67%+2.15%-30.78% 143B
Average +4.04%+2.26%+29.97%+56.42% 347.71B
Weighted average by Cap. +1.03%-1.82%+37.57%+83.01%

Financials

2024 2025
Net sales 55.86B 37.71M 32.96M 30.48M 27.97M 52.94M 3.63B 53.86M 364M 143M 1.77B 142M 139M 6.13B 60.02B 40.52M 35.42M 32.75M 30.06M 56.89M 3.9B 57.87M 391M 153M 1.91B 152M 149M 6.58B
Net income 3.52B 2.38M 2.08M 1.92M 1.76M 3.34M 229M 3.4M 22.92M 9M 112M 8.93M 8.73M 386M -755M -510K -445K -412K -378K -715K -49.11M -728K -4.91M -1.93M -23.98M -1.91M -1.87M -82.79M
Net Debt -12.84B -8.67M -7.58M -7.01M -6.43M -12.17M -835M -12.38M -83.58M -32.83M -408M -32.56M -31.84M -1.41B -29.05B -19.61M -17.14M -15.85M -14.55M -27.53M -1.89B -28.01M -189M -74.27M -923M -73.65M -72.03M -3.19B
Logo Samik Pharmaceutical Company LTD.
Samik Pharm Co Ltd is a Korea-based company engaged in the manufacturing and sales of pharmaceuticals business. The Company is mainly engaged in the manufacture of drugs such as circulatory machinery treatments such as Cesar Plus tablets and Eravix tablets, diabetes treatments such as Griffin tablets and Gluemser tablets, digestive machinery treatments such as Samik Pharmotidine tablets and Rebacode tablets, and antipyretic anti-inflammatory drugs such as Tamitrasemi tablets and Seklfen tablets. In addition, the Company is also engaged in the manufacturing of drugs such as treating acute or recurrent vaginal candidiasis, treating children with motion sickness, and treating alopecia. The Company sells its products in domestic and overseas markets.
Employees
-
Date Price Change Volume
26-07-16 ₩5,570.00 +29.84% 3,095,521
26-07-15 ₩4,290.00 +11.43% 2,382,100
26-07-14 ₩3,850.00 -3.51% 2,911,911
26-07-13 ₩3,990.00 -7.75% 158,943
26-07-10 ₩4,325.00 +4.34% 157,273
  1. Stock Market
  2. Stocks
  3. A014950 Stock